NCT07196124View on ClinicalTrials.gov

BCMA/GPRC5D CAR-T Therapy for Multiple Myeloma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

October 9, 2028

Study Completion Date

December 9, 2028

Conditions

Multiple Myeloma Refractory

Interventions

BIOLOGICAL

BCMA/GPRC5D CAR-T

A single infusion of BCMA/GPRC5D CAR-T Injection administered intravenously.

All Listed Sponsors

lead

Guangzhou Bio-gene Technology Co., Ltd

INDUSTRY